Valuation: Royalty Pharma plc

Market Cap 25.79B 22.54B 20.8B 19.17B 36.13B 2,484B 36.93B 249B 97.77B 1,216B 96.85B 94.73B 4,187B P/E 2026 *
22x
P/E 2027 * 15.3x
Enterprise Value 34.94B 30.54B 28.18B 25.97B 48.96B 3,365B 50.04B 337B 132B 1,648B 131B 128B 5,673B EV / Sales 2026 *
10.1x
EV / Sales 2027 * 9.48x
Free-Float
71.97%
Yield 2026 *
1.72%
Yield 2027 * 1.81%
1 day-0.60%
1 week+3.10%
Current month+3.76%
1 month+8.34%
3 months+16.36%
6 months+47.10%
Current year+50.57%
1 week 54.95
Extreme 54.95
59.44
1 month 52.89
Extreme 52.89
59.44
Current year 38.29
Extreme 38.29
59.44
1 year 34.08
Extreme 34.0805
59.44
3 years 24.05
Extreme 24.05
59.44
5 years 24.05
Extreme 24.05
59.44
10 years 24.05
Extreme 24.05
59.44
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Executive/Senior Manager

-9,099 0.0021%
6/30/26 Sell

Executive/Senior Manager

-130,000 0.0293%
6/30/26 Free

Director

689 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%+3.10%+64.03%+89.82% 25.79B
+0.85%-0.80%+54.84%+163.70% 1,051B
+1.23%-1.53%+55.26%+59.07% 609B
+0.04%+2.58%+32.96%+88.75% 450B
+0.78%-0.71%+30.04%+24.61% 330B
+1.41%+0.58%+33.92%+47.20% 284B
-0.27%-1.87%+22.13%+23.47% 263B
-1.76%+2.37%-22.19%-38.45% 223B
-1.42%+0.80%+22.81%+60.77% 198B
-1.48%+3.43%+23.42%+73.31% 167B
Average -0.17%+0.79%+31.72%+59.22% 360.09B
Weighted average by Cap. +0.21%+0.05%+37.94%+81.55%

Financials

2026 *2027 *
Net sales 3.47B 3.03B 2.8B 2.58B 4.86B 334B 4.97B 33.44B 13.15B 164B 13.03B 12.74B 563B 3.71B 3.24B 2.99B 2.75B 5.19B 357B 5.31B 35.72B 14.05B 175B 13.92B 13.61B 602B
Net income 1.65B 1.45B 1.33B 1.23B 2.32B 159B 2.37B 15.94B 6.27B 78.01B 6.21B 6.07B 269B 2.24B 1.95B 1.8B 1.66B 3.13B 215B 3.2B 21.56B 8.48B 106B 8.4B 8.22B 363B
Net Debt 9.15B 8B 7.38B 6.8B 12.82B 881B 13.11B 88.23B 34.7B 432B 34.38B 33.62B 1,486B 9.33B 8.15B 7.52B 6.93B 13.06B 898B 13.35B 89.88B 35.35B 440B 35.02B 34.25B 1,514B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-07-17 US$58.18 -0.60% 2,540,469
26-07-16 US$58.53 +3.94% 3,591,515
26-07-15 US$56.31 +1.15% 2,749,371
26-07-14 US$55.67 -1.38% 2,231,398
26-07-13 US$56.45 +0.04% 2,217,147
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
58.18USD
Average target price
59.89USD
Spread / Average Target
+2.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock